|
Ameya Deshpande, MS, says for APIs that are compatible with HME, careful attention to the formulation quality attributes that include excipient selection, dosage form design, analytical testing, and stability are required to maximize the efficacy and quality of the final product.
|
|
|
Masumi Dave, PhD, and Rollie Fuller monitor in this study ASA hydrolysis in different formulations using UPLC and TAM with the objective of comparing these methods for agreement, speed, and efficiency in predicting drug stability. In parallel, they assess the impact of the excipient choices on the stability of ASA.
|
|
|
Catherine Hanley, Vice President & Interim CDMO Business Unit Head at Emergent BioSolutions, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
|
|
|
Bob Wieden and Chun Wang, PhD, discuss how significant challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel polymeric drug delivery platform that overcomes a great many bioavailability and delivery obstacles.
|
|
|
|
|

Medical Engineering Technologies delivers excellence in combination device testing, globally. Services include: biocompatibility and chemical characterization, dose delivery accuracy, extractable and leachable studies, formulation stability, mechanical performance, RLD comparisons, sterile barrier verification, human factors studies, and lots of good advice. Medical Engineering Technologies is the destination for combination device batch release and design validation testing. Clients from across the globe have found our laboratory services to be rapid, precise, and very effective. MET has successfully delivered testing to medical device and pharmaceutical companies in over 20 countries across: Africa, Asia, Australasia, Europe, and the USA. Click here for more.
|